Mo. Elrggal
@kidneyman.bsky.social
Nephrologist, 🇪🇬, Father, NSMC, NephJC, ISNACT, ISNGTF, NDTsocial, PLOSONE, ESNT, JHAH
Reposted by Mo. Elrggal
large cohort study of
CDK 4/6
BRAF
EGFR
VEGF
and other cancer treatments
#OncoNephrology #NephSky #KidneyWk
jamanetwork.com/journals/jam... from Shuchi Anand et al from @stanfordmedicine.bsky.social
CDK 4/6
BRAF
EGFR
VEGF
and other cancer treatments
#OncoNephrology #NephSky #KidneyWk
jamanetwork.com/journals/jam... from Shuchi Anand et al from @stanfordmedicine.bsky.social
November 6, 2025 at 10:30 PM
large cohort study of
CDK 4/6
BRAF
EGFR
VEGF
and other cancer treatments
#OncoNephrology #NephSky #KidneyWk
jamanetwork.com/journals/jam... from Shuchi Anand et al from @stanfordmedicine.bsky.social
CDK 4/6
BRAF
EGFR
VEGF
and other cancer treatments
#OncoNephrology #NephSky #KidneyWk
jamanetwork.com/journals/jam... from Shuchi Anand et al from @stanfordmedicine.bsky.social
Reposted by Mo. Elrggal
Now live in #ASNJASN, simultaneously published with #KidneyWk: "Immunosuppression in Older Kidney Transplant Recipients: A Randomized Controlled Trial"
Read more: kidney.pub/JASN0924
Read more: kidney.pub/JASN0924
November 7, 2025 at 5:30 PM
Now live in #ASNJASN, simultaneously published with #KidneyWk: "Immunosuppression in Older Kidney Transplant Recipients: A Randomized Controlled Trial"
Read more: kidney.pub/JASN0924
Read more: kidney.pub/JASN0924
Reposted by Mo. Elrggal
Among more than 800 000 CKD-PC participants, discordance between cystatin C and creatinine eGFR values was associated with increased risk of death, cardiovascular events, and kidney failure.
#KidneyWK @asnkidney.bsky.social
ja.ma/4oV4DtU
#KidneyWK @asnkidney.bsky.social
ja.ma/4oV4DtU
November 7, 2025 at 8:15 PM
Among more than 800 000 CKD-PC participants, discordance between cystatin C and creatinine eGFR values was associated with increased risk of death, cardiovascular events, and kidney failure.
#KidneyWK @asnkidney.bsky.social
ja.ma/4oV4DtU
#KidneyWK @asnkidney.bsky.social
ja.ma/4oV4DtU
Reposted by Mo. Elrggal
In celebration of #KidneyWk, the entire November issue is FREE to access until November 30, 2025!
Check out the plain-language summaries on what inspired each study, the basic approach taken, what was learned, and why it matters:
bit.ly/3X1XpZj
Check out the plain-language summaries on what inspired each study, the basic approach taken, what was learned, and why it matters:
bit.ly/3X1XpZj
November 7, 2025 at 9:57 PM
In celebration of #KidneyWk, the entire November issue is FREE to access until November 30, 2025!
Check out the plain-language summaries on what inspired each study, the basic approach taken, what was learned, and why it matters:
bit.ly/3X1XpZj
Check out the plain-language summaries on what inspired each study, the basic approach taken, what was learned, and why it matters:
bit.ly/3X1XpZj
Reposted by Mo. Elrggal
Thoughtful and controversial blog from Last Month in Nephrology #NephSky #MedSy
Albuminuria as an ESKD surrogate may be a statistical mirage, limited by imprecision and overinterpretation
However, it moved nephrology forward and made studies happen
lastmonthinnephrology.wordpress.com
Albuminuria as an ESKD surrogate may be a statistical mirage, limited by imprecision and overinterpretation
However, it moved nephrology forward and made studies happen
lastmonthinnephrology.wordpress.com
Last Month in Nephrology
lastmonthinnephrology.wordpress.com
September 6, 2025 at 4:29 PM
Thoughtful and controversial blog from Last Month in Nephrology #NephSky #MedSy
Albuminuria as an ESKD surrogate may be a statistical mirage, limited by imprecision and overinterpretation
However, it moved nephrology forward and made studies happen
lastmonthinnephrology.wordpress.com
Albuminuria as an ESKD surrogate may be a statistical mirage, limited by imprecision and overinterpretation
However, it moved nephrology forward and made studies happen
lastmonthinnephrology.wordpress.com
Reposted by Mo. Elrggal
🤔 How often is end-stage kidney disease in patients with MCD/ FSGS? #NephSky #MedSky
@brianrifkin.bsky.social dissected the conclusions from the RaDar study in this #NephJCshorts
*the original article from @asnpublications.bsky.social
www.nephjc.com/news/nephjc-...
@brianrifkin.bsky.social dissected the conclusions from the RaDar study in this #NephJCshorts
*the original article from @asnpublications.bsky.social
www.nephjc.com/news/nephjc-...
NephJC Shorts: MCD and FSGS Outcomes — NephJC
A NephJC Shorts discussion of the long term data on kidney failure in FSGS and MCD
www.nephjc.com
September 6, 2025 at 5:00 PM
🤔 How often is end-stage kidney disease in patients with MCD/ FSGS? #NephSky #MedSky
@brianrifkin.bsky.social dissected the conclusions from the RaDar study in this #NephJCshorts
*the original article from @asnpublications.bsky.social
www.nephjc.com/news/nephjc-...
@brianrifkin.bsky.social dissected the conclusions from the RaDar study in this #NephJCshorts
*the original article from @asnpublications.bsky.social
www.nephjc.com/news/nephjc-...
Reposted by Mo. Elrggal
On 7/22/25 at 9pm EST only on Bluesky!
#NephSky #MedSky join us for a lively discussion.
We're debating eGFRdiff (the gap that is sometimes present between the eGFR of cystatin C and creatinine). What does it mean, what causes it and what you should do about it. #NephJC
www.nephjc.com/news/egfrdiff
#NephSky #MedSky join us for a lively discussion.
We're debating eGFRdiff (the gap that is sometimes present between the eGFR of cystatin C and creatinine). What does it mean, what causes it and what you should do about it. #NephJC
www.nephjc.com/news/egfrdiff
Mind The Gap: When eGFR Creatinine and Cystatin C Disagree — NephJC
This week, we will discuss the clinical significance of eGFRdiff, the difference in eGFRcys (cystatin C) and eGFRcr (creatinine).
www.nephjc.com
July 21, 2025 at 11:31 AM
On 7/22/25 at 9pm EST only on Bluesky!
#NephSky #MedSky join us for a lively discussion.
We're debating eGFRdiff (the gap that is sometimes present between the eGFR of cystatin C and creatinine). What does it mean, what causes it and what you should do about it. #NephJC
www.nephjc.com/news/egfrdiff
#NephSky #MedSky join us for a lively discussion.
We're debating eGFRdiff (the gap that is sometimes present between the eGFR of cystatin C and creatinine). What does it mean, what causes it and what you should do about it. #NephJC
www.nephjc.com/news/egfrdiff
Read this piece from the ERAKI working group at the @ndt-era.bsky.social regarding the results of the DEFENDER trial published last August @jama.com
academic.oup.com/ndt/article/...
academic.oup.com/ndt/article/...
July 13, 2025 at 11:20 PM
Read this piece from the ERAKI working group at the @ndt-era.bsky.social regarding the results of the DEFENDER trial published last August @jama.com
academic.oup.com/ndt/article/...
academic.oup.com/ndt/article/...
Reposted by Mo. Elrggal
We don’t get to discuss every important study that comes out on #NephJC
Hence #NephJCShorts
www.nephjc.com/news/nephjc-...
Hence #NephJCShorts
www.nephjc.com/news/nephjc-...
Introducing NephJC Shorts — NephJC
In just over a decade of critical appraisal on NephJC, we have done several experiments. Some of them have worked out phenomenally well, such as the Freely Filtered podcast. Others were not ready for ...
www.nephjc.com
July 2, 2025 at 6:45 PM
We don’t get to discuss every important study that comes out on #NephJC
Hence #NephJCShorts
www.nephjc.com/news/nephjc-...
Hence #NephJCShorts
www.nephjc.com/news/nephjc-...
Reposted by Mo. Elrggal
Enjoy the latest edition of ISN-ACT Global Trials Focus (GTF), a monthly list identifying and summarizing recent interesting trials relevant to kidney disease. Each trial is reviewed in context and assessed for its risk of bias in key areas ➡ http://lite.spr.ly/6...
Clinical Trials (ISN-ACT) - International Society of Nephrology
The ISN-Advancing Clinical Trials (ISN-ACT) is an ISN initiative to encourage existing infrastructures within ISN to improve the global nephrology community’s participation in clinical trial research.
lite.spr.ly
July 3, 2025 at 6:00 AM
Enjoy the latest edition of ISN-ACT Global Trials Focus (GTF), a monthly list identifying and summarizing recent interesting trials relevant to kidney disease. Each trial is reviewed in context and assessed for its risk of bias in key areas ➡ http://lite.spr.ly/6...
Reposted by Mo. Elrggal
On the #AJKDBlog, catch up on these interviews with:
- Oshozimhede E. Iyalomhe on statin use in CKD
- Roger Rodby and William Whittier about renal tubular acidoses
- Subhash Chander on urea as a tool for managing SIADH-induced hyponatremia
bit.ly/3ztk4VV (FREE)
- Oshozimhede E. Iyalomhe on statin use in CKD
- Roger Rodby and William Whittier about renal tubular acidoses
- Subhash Chander on urea as a tool for managing SIADH-induced hyponatremia
bit.ly/3ztk4VV (FREE)
July 3, 2025 at 10:01 AM
On the #AJKDBlog, catch up on these interviews with:
- Oshozimhede E. Iyalomhe on statin use in CKD
- Roger Rodby and William Whittier about renal tubular acidoses
- Subhash Chander on urea as a tool for managing SIADH-induced hyponatremia
bit.ly/3ztk4VV (FREE)
- Oshozimhede E. Iyalomhe on statin use in CKD
- Roger Rodby and William Whittier about renal tubular acidoses
- Subhash Chander on urea as a tool for managing SIADH-induced hyponatremia
bit.ly/3ztk4VV (FREE)
Reposted by Mo. Elrggal
Dr. Katherine Tuttle focuses her educational Grand Rounds talk on a reemerging topic: "New Approaches to Blocking #Aldosterone & #Angiotensinogen for #Hypertension or #CKD." #kidney #nephrology #nephsky
@uwmedicine.bsky.social
youtu.be/TeWkmCopuzk
@uwmedicine.bsky.social
youtu.be/TeWkmCopuzk
Kathy Tuttle, MD - New Approaches to Blocking Aldosterone & Angiotensinogen for Hypertension or CKD
YouTube video by University of Washington Division of Nephrology
youtu.be
May 9, 2025 at 8:11 PM
Dr. Katherine Tuttle focuses her educational Grand Rounds talk on a reemerging topic: "New Approaches to Blocking #Aldosterone & #Angiotensinogen for #Hypertension or #CKD." #kidney #nephrology #nephsky
@uwmedicine.bsky.social
youtu.be/TeWkmCopuzk
@uwmedicine.bsky.social
youtu.be/TeWkmCopuzk
Reposted by Mo. Elrggal
When @rajmehrotra.bsky.social is giving a talk on the factors for home dialysis stagnation and growth in US at the #CSNAGM
We get to see a CJASN abstract! From Divya Bajpai
We get to see a CJASN abstract! From Divya Bajpai
May 9, 2025 at 9:11 PM
When @rajmehrotra.bsky.social is giving a talk on the factors for home dialysis stagnation and growth in US at the #CSNAGM
We get to see a CJASN abstract! From Divya Bajpai
We get to see a CJASN abstract! From Divya Bajpai
Reposted by Mo. Elrggal
📣 Reminder!
ASDIN is accepting applications for the $25K Research Grant in Vascular Access — but don’t wait!
🗓 Applications close July 15, 2025.
Click here to learn more: www.asdin.org/news/699844/...
#vascularaccess #ASDIN #researchgrant #nephrology
ASDIN is accepting applications for the $25K Research Grant in Vascular Access — but don’t wait!
🗓 Applications close July 15, 2025.
Click here to learn more: www.asdin.org/news/699844/...
#vascularaccess #ASDIN #researchgrant #nephrology
May 9, 2025 at 5:36 PM
📣 Reminder!
ASDIN is accepting applications for the $25K Research Grant in Vascular Access — but don’t wait!
🗓 Applications close July 15, 2025.
Click here to learn more: www.asdin.org/news/699844/...
#vascularaccess #ASDIN #researchgrant #nephrology
ASDIN is accepting applications for the $25K Research Grant in Vascular Access — but don’t wait!
🗓 Applications close July 15, 2025.
Click here to learn more: www.asdin.org/news/699844/...
#vascularaccess #ASDIN #researchgrant #nephrology
Reposted by Mo. Elrggal
Use of SGLT2 inhibitors (SGLT2i) in ADPKD is not "presently" recommended, because people with ADPKD have been excluded from the clinical trials; thus, its safety has not been evaluated (from @kdigo.org)
#Nephpearls #NephSky
👉 kdigo.org/guidelines/a...
#Nephpearls #NephSky
👉 kdigo.org/guidelines/a...
May 9, 2025 at 7:11 PM
Use of SGLT2 inhibitors (SGLT2i) in ADPKD is not "presently" recommended, because people with ADPKD have been excluded from the clinical trials; thus, its safety has not been evaluated (from @kdigo.org)
#Nephpearls #NephSky
👉 kdigo.org/guidelines/a...
#Nephpearls #NephSky
👉 kdigo.org/guidelines/a...
Reposted by Mo. Elrggal
Finerenone reduced kidney and cardiovascular events in CKD and T2D patients, regardless of frailty. Benefits included lower albuminuria and slower eGFR decline, supporting its use even in frail individuals.
#podocytetalk #Nephpearls #Nephrology #CKD
journals.lww.com/cjasn/abstra...
#podocytetalk #Nephpearls #Nephrology #CKD
journals.lww.com/cjasn/abstra...
May 10, 2025 at 8:47 AM
Finerenone reduced kidney and cardiovascular events in CKD and T2D patients, regardless of frailty. Benefits included lower albuminuria and slower eGFR decline, supporting its use even in frail individuals.
#podocytetalk #Nephpearls #Nephrology #CKD
journals.lww.com/cjasn/abstra...
#podocytetalk #Nephpearls #Nephrology #CKD
journals.lww.com/cjasn/abstra...
Reposted by Mo. Elrggal
Sparsentan is now approved for the treatment of IgAN in European Union countries. #igan #iganephropathy #kidneydisease #nephrology #nephsky www.docwirenews.com/post/eu-appr...
EU Approves Sparsentan for Treatment of IgAN | Docwire News
The European Commission has granted standard approval to sparsentan for the treatment of adults with primary IgA nephropathy (IgAN).
www.docwirenews.com
May 8, 2025 at 8:50 PM
Sparsentan is now approved for the treatment of IgAN in European Union countries. #igan #iganephropathy #kidneydisease #nephrology #nephsky www.docwirenews.com/post/eu-appr...
Reposted by Mo. Elrggal
SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors
This cohort study evaluates the association between sodium-glucose cotransporter 2 inhibitors and hyperkalemia in individuals with diabetes, heart failure, or chronic kidney disease receiving renin-an...
jamanetwork.com
May 9, 2025 at 2:45 PM
SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Reposted by Mo. Elrggal
Do you prescribe SGLT2 inhibitors (SGLT2i) for patients with ADPKD?
#Nephpearls #AskRenal #NephSky
❤️ LIKE for YES (and why?)
❌ X for NO (and why?)
👉 pubmed.ncbi.nlm.nih.gov/39099568/
#Nephpearls #AskRenal #NephSky
❤️ LIKE for YES (and why?)
❌ X for NO (and why?)
👉 pubmed.ncbi.nlm.nih.gov/39099568/
May 9, 2025 at 3:20 PM
Do you prescribe SGLT2 inhibitors (SGLT2i) for patients with ADPKD?
#Nephpearls #AskRenal #NephSky
❤️ LIKE for YES (and why?)
❌ X for NO (and why?)
👉 pubmed.ncbi.nlm.nih.gov/39099568/
#Nephpearls #AskRenal #NephSky
❤️ LIKE for YES (and why?)
❌ X for NO (and why?)
👉 pubmed.ncbi.nlm.nih.gov/39099568/
Do you allow hemodialysis patients with permanent HD catheters to shower?
Yes
No
Other, please state
www.ajkd.org/article/S027...
#nephinp
#nephrology_in_practice
@ajkd.bsky.social
Yes
No
Other, please state
www.ajkd.org/article/S027...
#nephinp
#nephrology_in_practice
@ajkd.bsky.social
Patient and Health Care Provider Perspectives on Showering for Patients With Hemodialysis Central Venous Catheters: A Survey Study
Patients on hemodialysis using a central venous catheter (CVC) are often advised not
to shower due to infection risk. This study assessed practices and attitudes of patients
and health care providers ...
www.ajkd.org
May 7, 2025 at 9:23 PM
Do you allow hemodialysis patients with permanent HD catheters to shower?
Yes
No
Other, please state
www.ajkd.org/article/S027...
#nephinp
#nephrology_in_practice
@ajkd.bsky.social
Yes
No
Other, please state
www.ajkd.org/article/S027...
#nephinp
#nephrology_in_practice
@ajkd.bsky.social
Reposted by Mo. Elrggal
Progress, challenges, and pragmatic concessions in predicting relative risk of kidney survival in ARPKD
doi.org/10.1016/j.kint.2025.02.018
Original article: doi.org/10.1016/j.kint.2025.01.023
#KICommentary #MedSky #NephSky #polycystickidneydisease
doi.org/10.1016/j.kint.2025.02.018
Original article: doi.org/10.1016/j.kint.2025.01.023
#KICommentary #MedSky #NephSky #polycystickidneydisease
May 7, 2025 at 4:10 PM
Progress, challenges, and pragmatic concessions in predicting relative risk of kidney survival in ARPKD
doi.org/10.1016/j.kint.2025.02.018
Original article: doi.org/10.1016/j.kint.2025.01.023
#KICommentary #MedSky #NephSky #polycystickidneydisease
doi.org/10.1016/j.kint.2025.02.018
Original article: doi.org/10.1016/j.kint.2025.01.023
#KICommentary #MedSky #NephSky #polycystickidneydisease
Reposted by Mo. Elrggal
Alternative complement pathway dysregulation in CKD and CKD progression, endothelial inflammation and cardiovascular outcomes… room for complement inhibitors beyond complement-mediated kidney diseases?
www.jci.org/articles/vie...
#NephSky #MedSky
www.jci.org/articles/vie...
#NephSky #MedSky
Aberrant activation of complement's alternative pathway may be the missing link in understanding how vascular and systemic inflammation accelerates chronic kidney disease progression.
Read more in the review by Jalal, Thurman & Smith: buff.ly/DwHd0ut
Read more in the review by Jalal, Thurman & Smith: buff.ly/DwHd0ut
May 6, 2025 at 11:02 PM
Alternative complement pathway dysregulation in CKD and CKD progression, endothelial inflammation and cardiovascular outcomes… room for complement inhibitors beyond complement-mediated kidney diseases?
www.jci.org/articles/vie...
#NephSky #MedSky
www.jci.org/articles/vie...
#NephSky #MedSky
Reposted by Mo. Elrggal
Editorial by Harshil A. Fichadiya and John C. Lieske:
Do Topiramate and Zonisamide Cause Kidney Stones?
bit.ly/FichadiyaED25 (FREE)
Do Topiramate and Zonisamide Cause Kidney Stones?
bit.ly/FichadiyaED25 (FREE)
May 7, 2025 at 4:06 PM
Editorial by Harshil A. Fichadiya and John C. Lieske:
Do Topiramate and Zonisamide Cause Kidney Stones?
bit.ly/FichadiyaED25 (FREE)
Do Topiramate and Zonisamide Cause Kidney Stones?
bit.ly/FichadiyaED25 (FREE)
Reposted by Mo. Elrggal
#KIControversies in Nephrology
Clinical utility of donor-derived cell-free DNA 🧬testing for kidney transplant monitoring in selected patients
You can read the
✅Point
✅Counterpoint
✅Editor's summary
in the May issue of KI
doi.org/10.1016/j.kint.2025.01.039
#MedSky #NephSky #kidneytransplant
Clinical utility of donor-derived cell-free DNA 🧬testing for kidney transplant monitoring in selected patients
You can read the
✅Point
✅Counterpoint
✅Editor's summary
in the May issue of KI
doi.org/10.1016/j.kint.2025.01.039
#MedSky #NephSky #kidneytransplant
May 7, 2025 at 5:48 PM
#KIControversies in Nephrology
Clinical utility of donor-derived cell-free DNA 🧬testing for kidney transplant monitoring in selected patients
You can read the
✅Point
✅Counterpoint
✅Editor's summary
in the May issue of KI
doi.org/10.1016/j.kint.2025.01.039
#MedSky #NephSky #kidneytransplant
Clinical utility of donor-derived cell-free DNA 🧬testing for kidney transplant monitoring in selected patients
You can read the
✅Point
✅Counterpoint
✅Editor's summary
in the May issue of KI
doi.org/10.1016/j.kint.2025.01.039
#MedSky #NephSky #kidneytransplant
When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases
academic.oup.com/ndt/article/...
An amazing article from the high impact articles published by @ndt-era.bsky.social
academic.oup.com/ndt/article/...
An amazing article from the high impact articles published by @ndt-era.bsky.social
When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases
ABSTRACT. Kidney disease frequently coexists with cardiovascular (CV) diseases, and this dual presence significantly amplifies the risk of adverse clinical
academic.oup.com
May 3, 2025 at 12:00 PM
When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases
academic.oup.com/ndt/article/...
An amazing article from the high impact articles published by @ndt-era.bsky.social
academic.oup.com/ndt/article/...
An amazing article from the high impact articles published by @ndt-era.bsky.social